

BCL9 Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant BCL9. Catalog # AT1286a

Product Information

| Application | WB, IF, E |
|-------------------|------------------|
| Primary Accession | <u>000512</u> |
| Other Accession | <u>NM_004326</u> |
| Reactivity | Human |
| Host | mouse |
| Clonality | monoclonal |
| Isotype | IgG1 kappa |
| Clone Names | 2D4 |
| Calculated MW | 149290 |

Additional Information

| Gene ID | 607 |
|--------------------|---|
| Other Names | B-cell CLL/lymphoma 9 protein, B-cell lymphoma 9 protein, Bcl-9, Protein legless homolog, BCL9 |
| Target/Specificity | BCL9 (NP_004317, 1036 a.a. ~ 1135 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Dilution | WB~~1:500~1000 IF~~1:50~200 E~~N/A |
| Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
| Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Precautions | BCL9 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |

Background

BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.

References

Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor. Miller TC, et al. J Mol Biol, 2010 Sep 3. PMID 20637214.Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with

ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. Mol Med, 2010 Jul-Aug. PMID 20379614.Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Talmud PJ, et al. Am J Hum Genet, 2009 Nov. PMID 19913121.BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Mani M, et al. Cancer Res, 2009 Oct 1. PMID 19738061.

Images



Antibody Reactive Against Recombinant Protein.Western Blot detection against Immunogen (36.74 KDa) .



Immunofluorescence of monoclonal antibody to BCL9 on HeLa cell. [antibody concentration 10 ug/ml]



Detection limit for recombinant GST tagged BCL9 is approximately 0.03ng/ml as a capture antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.